Caplin Point Laboratories Ltd (CAPLIPOINT) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap

Caplin Point Lab Share Price

1,973 -3.85 -0.19%
as on 05-Dec'25 15:26

Caplin Point Laboratories Ltd (CAPLIPOINT) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Caplin Point Lab

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Caplin Point Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
25.52
Market Cap:
15,026.4 Cr.
52-wk low:
1,551.1
52-wk high:
2,636

Is Caplin Point Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Caplin Point Lab: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Caplin Point Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 55.4%69%64.1%45.6%33.4%28.8%28.8%26.9%26.9%26.2%-
Value Creation
Index
3.03.93.62.31.41.11.11.01.00.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3184025406498631,0611,2691,4671,6941,9372,040
Sales YoY Gr.-26.2%34.4%20.2%33.1%23%19.6%15.5%15.5%14.4%-
Adj EPS 8.412.418.622.325.932.438.648.559.268.677.5
YoY Gr.-46.9%50.2%20%16.1%25.2%18.9%25.7%22.1%16%-
BVPS (₹) 21.729.747.778114.2144.9183.9235.9293.2362.7415.6
Adj Net
Profit
63.693.5141169196245292367449522589
Cash Flow from Ops. 56.567.666.583.444.7269337271318432-
Debt/CF from Ops. 0.10000.80.10000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 22.2%17.6%15.1%14.4%
Adj EPS 26.3%21.5%21.2%16%
BVPS36.8%26%25.4%23.7%
Share Price 21.6% 32% 37.1% -16.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
43.15347.733.824.82321.921.821.420.219.9
Op. Profit
Mgn %
28.131.236.235.730.13131.130.132.633.634.2
Net Profit
Mgn %
2023.3262622.72423.725.126.827.228.9
Debt to
Equity
00000000000
Working Cap
Days
716795133176197211221225238194
Cash Conv.
Cycle
-68-51-19331121159498115109168

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Caplin Point Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 46 77.5
TTM Sales (₹ Cr.) 717 2,040
BVPS (₹.) 242.5 415.6
Reserves (₹ Cr.) 1,828 3,144
P/BV 8.15 4.76
PE 42.97 25.52
From the Market
52 Week Low / High (₹) 1551.05 / 2636.00
All Time Low / High (₹) 0.18 / 2636.00
Market Cap (₹ Cr.) 15,026
Equity (₹ Cr.) 15.2
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Caplin Point Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Caplin Point Lab - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Caplin Point Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2394025406498631,0611,2691,4671,6941,937
Operating Expenses 1752773454176037378751,0261,1431,291
Manufacturing Costs223848578386103117151158
Material Costs121185238289413472558663724771
Employee Cost 1830384667102115136143177
Other Costs 14242125407799110125185
Operating Profit 64125195232260324395441551647
Operating Profit Margin (%) 26.9%31.1%36.2%35.7%30.1%30.6%31.1%30.0%32.6%33.4%
Other Income 4101319412839576796
Interest 0111021111
Depreciation 7131923323747455366
Exceptional Items 0000000000
Profit Before Tax 60121188227269314386451564677
Tax 1425445054627774103136
Profit After Tax 4696145177215251308377461541
PAT Margin (%) 19.2%23.8%26.8%27.2%24.9%23.7%24.3%25.7%27.2%27.9%
Adjusted EPS (₹)6.112.719.223.328.432.039.649.660.270.6
Dividend Payout Ratio (%)20%12%10%9%9%9%10%9%8%9%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1272253616269381,1711,4681,8652,3012,831
Share Capital 15151551909090909090
Reserves 1112103455758491,0811,3791,7752,2122,741
Minority Interest000091826273136
Debt1000001301
Long Term Debt1000000000
Short Term Debt0000001301
Trade Payables567994606489156153230218
Others Liabilities 845445561148779130123121
Total Liabilities 2673585007431,1261,3641,7302,1772,6863,206

Fixed Assets

Gross Block181195232272355423446480702860
Accumulated Depreciation3743624582117159201250314
Net Fixed Assets 144152169227273305287280453546
CWIP 031510201418221117144
Investments 0174770611189281376590
Inventories19222837238179227288363336
Trade Receivables833126160229279317394543632
Cash Equivalents 689379153223438463493553591
Others Assets 2737358682136329220282366
Total Assets 2673585007431,1261,3641,7302,1772,6863,206

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 4268668345269337271318432
PBT 60121188227269314386451564677
Adjustment 491519723301226
Changes in Working Capital -5-38-100-120-177-22-104-139-122
Tax Paid -16-24-36-43-55-66-81-88-109-128
Cash Flow From Investing Activity -6-36-69-100-55-29-377-218-320-335
Capex -8-25-49-65-77-73-91-193-146-192
Net Investments 0-17-27-201024-200-49-93-221
Others 267-151320-8525-8178
Cash Flow From Financing Activity -14-7-129080-24-41-28-38-38
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -0-0-0-0-0-19-17000
Interest Paid -0-0-0-0-0-2-1-1-1-1
Dividend Paid -14-6-11-15-33-3-23-30-34-38
Others 000105113-0-13-30
Net Cash Flow 2325-147370215-8126-4059

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)43.1354.9749.4337.1429.5825.6524.7723.6822.9721.72
ROCE (%)55.4169.0364.0845.5933.3528.8228.7726.8526.9226.22
Asset Turnover Ratio0.961.281.261.040.920.850.820.750.70.66
PAT to CFO Conversion(x)0.910.710.460.470.211.071.090.720.690.8
Working Capital Days
Receivable Days1019548082878688101111
Inventory Days25191719587258647066
Payable Days147133132985559808596106

Caplin Point Laboratories Ltd Stock News

Caplin Point Laboratories Ltd FAQs

The current trading price of Caplin Point Lab on 05-Dec-2025 15:26 is ₹1,973.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Caplin Point Lab stood at ₹15,026.4.
The latest P/E ratio of Caplin Point Lab as of 04-Dec-2025 is 42.97.
The latest P/B ratio of Caplin Point Lab as of 04-Dec-2025 is 8.15.
The 52-week high of Caplin Point Lab is ₹2,636 and the 52-week low is ₹1,551.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Caplin Point Lab is ₹716.6 ( Cr.) .

About Caplin Point Laboratories Ltd

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×